Start
Completion

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

RecruitingRegisteredCTG

Proof-of-concept randomised clinical trial (n=30) of psilocybin-enhanced psychotherapy (two oral doses 25–30 mg) versus treatment-as-usual among veterans in residential treatment for methamphetamine use disorder.

Details

Randomised, parallel-group study in veterans admitted to residential rehabilitation comparing psilocybin-enhanced psychotherapy (4 preparatory visits, 2 dosing sessions, 8 integration visits) with treatment-as-usual.

Primary aims are acceptability, feasibility, and safety with primary endpoint at end of intervention; secondary aims assess preliminary efficacy for methamphetamine use disorder and overall functioning at 60- and 180-day follow-ups.

Topics:Substance Use Disorders (SUD)

Registry

Registry linkNCT04982796